<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623596</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720DUS09</org_study_id>
    <nct_id>NCT01623596</nct_id>
  </id_info>
  <brief_title>Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.</brief_title>
  <acronym>PREFERMS</acronym>
  <official_title>A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to
      fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have
      only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) .
      Patients will be able to switch to different treatment for safety, efficacy, tolerability or
      convenience during the study.

      Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on
      treatment. Secondary objectives are to compare reasons for discontinuation, adverse events,
      cognitive impairment, medication satisfaction and change in brain volume measured by MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      852 Patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved
      first line DMTs. Patients must be either treatment naive or have received treatment with only
      one class of treatment (interferon beta preparation or glatiramer acetate) . Patients
      previously treated with DMT and randomized to the DMT arm may not remain on the same
      treatment for the study and will have to switch to a different class (i.e., previously
      treated with glatiramer acetate will switch to interferon beta preparaption, previously
      treated with interferon beta preparation will swtich to glatiramer acetate).

      Entry criteria at screening include but are not limited to, age 18-65, diagnosis with RRMS,
      EDSS &lt; or equal to 6, not pregnant or planning pregnancy and women of childbearing potential
      willing to use contraception throughout the study.

      Exclusion criteria include but are not limited to - prior exposure to fingolimod, history of
      malignancy within 5 years, other than RRMS types of MS, other diseases of the immune system,
      active macular edema, systemic bacterial, viral or fungal infections, patients without
      vaccine against varicella zoster, receipt of live or attentuated vaccines within a month of
      screening, history of various cardiac conditions, presence of certain ECG abnormalities,
      resting heart rate &lt; 45 bpm, symptomatic bradycardia, recurrent syncope, severe untreated
      sleep apnea, severe pulmonary conditions, various hepatic conditions, certain neurologic
      disorders, pregnancy.

      Patients may switch treatment before 3 months for safety reasons only, after 3 months for
      safety, efficacy, tolerability or convenience. Treatment switch during the study may be to
      any of study approved treatments irrespective of prior treatment.

      Patients randomized to fingolimod will need to have 6 hours of observation for signs and
      symptoms of bradycardia following administration of the first dose. Extended observation or
      overnight observation may be necessary under certain circumstances. Primary objective is to
      evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary
      objectives are to compare reasons for discontinuation, adverse events, cognitive impairment,
      medication satisfaction and change in brain volume measured by MRI. Exploratory objectives
      include annualized relapse rate, OCT, MRI evaluations, biomarkers and patient reported
      outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2012</start_date>
  <completion_date type="Actual">July 13, 2015</completion_date>
  <primary_completion_date type="Actual">July 13, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Retention Rate Over 12 Months</measure>
    <time_frame>at 12 months</time_frame>
    <description>Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set</measure>
    <time_frame>at 12 months</time_frame>
    <description>Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment
Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants
Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants
Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)</measure>
    <time_frame>baseline, 6 months, 12 months, and Last assessment which is either at Month 12 or at early discontinuation</time_frame>
    <description>Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons
The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.
NOTE: Higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)</measure>
    <time_frame>baseline, 6 months, 12 months, Last assessment which is either at Month 12 or at early discontinuation</time_frame>
    <description>Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons
The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.
NOTE: Higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From in Brain Volume From Month 12 to Last Visit (Randomized)</measure>
    <time_frame>12 months, and Last assessment which is either at Month 12 or at early discontinuation</time_frame>
    <description>Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months, 9 months, at 12 months &amp; Last assessment during randomized phase which is either at Month 12 or at early discontinuation</time_frame>
    <description>Summary statistics for Medication Satisfaction Questionnaire[Question: &quot;Overall, how satisfied are you with your current medication?&quot;] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">881</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fingolimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease Modifying Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod</intervention_name>
    <arm_group_label>Fingolimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disease Modifying therapy</intervention_name>
    <arm_group_label>Disease Modifying Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. written informed consent must be obtained prior to any assessment being performed.

          2. Male and female patients aged 18-65 years inclusive.

          3. Patients diagnosed with relapsing remitting MS, defined by the 2010 revised McDonald
             criteria (Pollman et al, 2011) (Appendix 1).

          4. EDSS score of less than or equal to 6.

          5. Patients naive to treatment or who have been treated with no more than one class of
             DMT previously (interferon β preparation or glatiramer acetate), and who, per
             investigator judgment, may benefit from a change of treatment class.

          6. Patients who have been treated with DMF for less than 2 months total exposure and who
             have a normal lymphocyte count at screening.

          7. Women of childbearing potential must have a negative urine and serum β-human chorionic
             gonadotropin (β-hCG) pregnancy test at screening and at baseline.

          8. Before entry women must be:

               -  Post menopausal for at least 1 year, or

               -  Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
                  ligation or otherwise incapable of pregnancy, or

               -  Practicing a highly effective method of birth control if sexually active,
                  including hormonal prescription oral contraceptives, contraceptive injections,
                  contraceptive patch, intrauterine device, double barrier method (e.g., condoms,
                  diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner
                  sterilization consistent with local regulations regarding use of birth control
                  methods for patients participating in clinical trials, for the duration of their
                  participation in the study, or

               -  Not heterosexually active (patients who are not heterosexually active at
                  screening must agree to utilize a highly effective method of birth control if
                  they become heterosexually active during their participation in the study) 4.2
                  Exclusion criteria

          1. Use of other investigational drugs within 30 days of screening.

          2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes.

          3. Prior exposure to fingolimod or any other S1P receptor modulating compounds.

          4. History or presence of malignancy of any organ system (other than successfully treated
             basal or squamous cell carcinoma of the skin or stage 0 carcinoma of the cervix),
             treated or untreated, within the past 5 years, regardless of whether there is evidence
             of local recurrence or metastases.

          5. Patients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Primary
             Progressive MS (PPMS).

          6. Patients with a history of chronic disease of the immune system other than MS or a
             known immunodeficiency syndrome.

          7. Patients who have been treated with:

             • Natalizumab, mitoxantrone, cladribine, rituximab, alemtuzumab, ofatumumab,
             ocrelizumab at any time before randomization

             • Immunoglobulins, or pulse of corticosteroids with more than 6 months cumulative
             exposure

             • Immunosuppressive/chemotherapeutic medications (e.g., methotrexate, azathioprine,
             cyclophosphamide, cellcept, Cytoxan, IVIG) with more than 6 months of cumulative
             exposure and within 6 months prior to randomization

             • Corticosteroids or adrenocorticotropic hormones in the past 30 days before
             randomization. Patients that require corticosteroids for a relapse during the
             screening period may be rescreened 30 days after the last dose.

          8. History of treatment with both classes of approved first line DMT (interferon β
             preparation and glatiramer acetate) or DMF exposure of 2 months or longer.

          9. Patients with uncontrolled diabetes mellitus (HbA1c &gt; 7%).

         10. Diagnosis of macular edema during the screening phase. Patients with a history of
             macular edema will be allowed to enter the study provided that they do not have
             macular edema at the screening visit.

         11. Patients with active systemic bacterial, viral or fungal infections, or known to have
             AIDS, Hepatitis B, Hepatitis C infection or positive HIV antibody, Hepatitis B surface
             antigen or Hepatitis C antibody tests.

         12. Patients without history of chickenpox or without vaccination against varicella-zoster
             virus at screening (patients may be vaccinated and rescreened one month or longer
             after vaccination).

         13. Patients who have received any live or live attenuated vaccines (including for
             varicella-zoster or measles) within 1 month prior to baseline.

         14. Patients with any medically unstable condition as assessed by the investigator.

         15. Patients with a history of the following cardiovascular conditions:

             • Cardiac arrest.

             • myocardial infarction, unstable angina, stroke, transient ischemic attack,
             decompensated heart failure requiring hospitalization, or Class III/IV heart failure
             (Appendix 3).

             • Congestive heart failure.

             • Hypertension that is not controlled with prescribed medications. These patients may
             be rescreened if blood pressure is stabilized with treatment.

             • Cerebrovascular disease.

             • History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick
             sinus syndrome, unless patient has a pacemaker.

             • Patients at higher risk of symptomatic bradycardia or heart block because of a
             coexisting medical condition or certain concomitant medications.

             • Patients randomized to the fingolimod arm with prolonged QTc interval at screening
             (corrected QT interval &gt; 450 ms in males and &gt; 470 ms in females); for patients
             randomized to the fingolimod treatment arm before dosing (baseline) or during the
             6-hour observation period; and those patients at additional risk for QT prolongation
             (e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on a concomitant
             therapy with QT prolonging drugs with a known risk of Torsades de pointes (e.g.,
             citalopram, chlorpromazine, haloperidol, methadone, erythromycin).

               -  Patients receiving class Ia or Class III antiarrhythmic drugs (Appendix 6)

               -  Patients receiving concurrent therapy with drugs that slow the heart rate or
                  atrioventricular conduction (e.g., beta blockers, digoxin, or heart-rate slowing
                  calcium channel blockers such as diltiazem, verapamil or digoxin). The
                  possibility to switch to drugs that do not slow the heart rate or
                  atrioventricular conduction should be evaluated by the physician prescribing
                  these drugs before initiating fingolimod treatment.

               -  History of sick sinus syndrome or sinoatrial heart block.

               -  Resting heart rate of &lt; 45 bpm or symptomatic bradycardia

               -  Recurrent syncope

               -  Severe untreated sleep apnea

         16. Patients with severe pulmonary conditions (including severe respiratory disease,
             pulmonary fibrosis, active tuberculosis, severe or poorly controlled asthma).

         17. Patients with any of the following hepatic conditions:

             • Chronic liver or biliary disease

               -  Total bilirubin greater than upper limit of normal (ULN) at screening unless in
                  the context of Gilbert's syndrome

               -  Conjugated bilirubin greater than the ULN at screening

               -  AST (SGOT), ALT (SGPT) greater than 3 times ULN at screening

               -  Alkaline phosphatase (AP) greater than 1.5 times the ULN at screening

         18. Serum creatinine greater than 2.0 mg/dL (176.5 µmol/L) at screening.

         19. Patients with the following neurological/psychiatric disorders:

               -  History of substance abuse (drug or alcohol) in the past five years as determined
                  by the investigator

               -  Progressive neurological disorder other than MS which may affect study
                  participation as determined by the investigator

               -  Any serious psychiatric condition that may interfere with the patient's ability
                  to cooperate and comply with the study procedures as determined by the
                  investigator

         20. Women who are pregnant or nursing (lactating) or planning to become pregnant.

         21. Any condition that in the opinion of the investigator, would compromise the well-being
             of the patient or the conduct of the study, or prevent the patient from meeting or
             performing study requirements.

         22. Pre-planned surgery or medical procedure that would interfere with the conduct of the
             study.

         23. Employee of the sponsor, investigator or study center, with direct involvement in the
             proposed study or other studies under the direction of that investigator or study
             center, as well as family members of the employees or the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <zip>72120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basalt</city>
        <state>Colorado</state>
        <zip>81621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dover</city>
        <state>Delaware</state>
        <zip>19901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462-6608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Flossmoor</city>
        <state>Illinois</state>
        <zip>60422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314-2611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hawesville</city>
        <state>Kentucky</state>
        <zip>42384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fulton</city>
        <state>Maryland</state>
        <zip>20759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684-2340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nixa</city>
        <state>Missouri</state>
        <zip>65714-7807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Ohio</state>
        <zip>44811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greensburg</city>
        <state>Pennsylvania</state>
        <zip>15601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neenah</city>
        <state>Wisconsin</state>
        <zip>54956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guaynabo</city>
        <zip>00968</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/searchbystudyid.nov?studyId=CFTY720DUS09</url>
    <description>Novartis Clinical Trial Results database</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <results_first_submitted>July 13, 2016</results_first_submitted>
  <results_first_submitted_qc>December 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2018</results_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>62 Fingolimod arm participants discontinued: 57 discontinued before treatment switch, and 5 discontinued after treatment switch
100 MS-DMT arm participants discontinued before treatment switch: 57 discontinued before treatment switch, and 43 discontinued after treatment switch</recruitment_details>
      <pre_assignment_details>Patient disposition was summarized on the Randomized Set.
Randomized Set (RS): consists of all participants who were assigned randomization numbers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fingolimod</title>
          <description>fingolimod 0.5 mg once a day</description>
        </group>
        <group group_id="P2">
          <title>Disease Modifying Therapy</title>
          <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="436"/>
                <participants group_id="P2" count="439"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>On Randomized Treatment</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>On Switched Treatment</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="339"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set (RS): consists of all patients who were assigned randomization numbers. The participants in this set were called randomized participants. This set was used to summarize participant disposition, demographic and baseline characteristics, and protocol deviation information. Participants were grouped according to randomized treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Fingolimod</title>
          <description>fingolimod 0.5 mg once a day</description>
        </group>
        <group group_id="B2">
          <title>Disease Modifying Therapy (MS_DMT)</title>
          <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="436"/>
            <count group_id="B2" value="439"/>
            <count group_id="B3" value="875"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="10.84"/>
                    <measurement group_id="B2" value="41.9" spread="10.39"/>
                    <measurement group_id="B3" value="41.7" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="640"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Retention Rate Over 12 Months</title>
        <description>Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)</description>
        <time_frame>at 12 months</time_frame>
        <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod</title>
            <description>fingolimod 0.5 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Disease Modifying Therapy (MS-DMT)</title>
            <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Retention Rate Over 12 Months</title>
          <description>Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)</description>
          <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set</title>
        <description>Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment
Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants
Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants
Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.</description>
        <time_frame>at 12 months</time_frame>
        <population>Randomized set (RS): consists of all patients who were assigned randomization numbers.
The patients in this set were called randomized patients. This set was used to summarize patient disposition, demographic and baseline characteristics, and protocol deviation information. Patients were grouped according to randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod</title>
            <description>fingolimod 0.5 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Disease Modifying Therapy (MS-DMT)</title>
            <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
          </group>
        </group_list>
        <measure>
          <title>Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set</title>
          <description>Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment
Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants
Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants
Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.</description>
          <population>Randomized set (RS): consists of all patients who were assigned randomization numbers.
The patients in this set were called randomized patients. This set was used to summarize patient disposition, demographic and baseline characteristics, and protocol deviation information. Patients were grouped according to randomized treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occurrence of relapse (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease activity present in MRI (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reaction (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu-like symptoms (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipoatrophy (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic side effects (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spasticity (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macular edema (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Needle phobia (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconvenient administration (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frequency of injections (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing antibodies present (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Primary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occurrence of relapse (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease activity present in MRI (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reaction (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu-like symptoms (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipoatrophy (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic side effects (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spasticity (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macular edema (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Needle phobia (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconvenient administration (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frequency of injections (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing antibodies present (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Secondary reason)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)</title>
        <description>Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons
The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.
NOTE: Higher scores indicate better performance.</description>
        <time_frame>baseline, 6 months, 12 months, and Last assessment which is either at Month 12 or at early discontinuation</time_frame>
        <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod</title>
            <description>fingolimod 0.5 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Disease Modifying Therapy (MS-DMT)</title>
            <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)</title>
          <description>Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons
The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.
NOTE: Higher scores indicate better performance.</description>
          <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
          <units>SDMT score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=76,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.00" spread="12.12"/>
                    <measurement group_id="O2" value="51.60" spread="13.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 6 months (n=70,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="8.09"/>
                    <measurement group_id="O2" value="0.20" spread="10.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 months (n=58, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="7.09"/>
                    <measurement group_id="O2" value="1.40" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Last assessment (n=73, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="7.77"/>
                    <measurement group_id="O2" value="0.40" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)</title>
        <description>Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons
The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.
NOTE: Higher scores indicate better performance.</description>
        <time_frame>baseline, 6 months, 12 months, Last assessment which is either at Month 12 or at early discontinuation</time_frame>
        <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod</title>
            <description>fingolimod 0.5 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Disease Modifying Therapy (MS-DMT)</title>
            <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)</title>
          <description>Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons
The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.
NOTE: Higher scores indicate better performance.</description>
          <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
          <units>SDMT score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=355,348)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.90" spread="18.26"/>
                    <measurement group_id="O2" value="48.50" spread="20.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 6 months (n=339,322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="14.04"/>
                    <measurement group_id="O2" value="0.70" spread="13.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 months (n=282,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="16.02"/>
                    <measurement group_id="O2" value="0.40" spread="14.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Last assessment (n=342, 324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="16.27"/>
                    <measurement group_id="O2" value="0.70" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From in Brain Volume From Month 12 to Last Visit (Randomized)</title>
        <description>Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI</description>
        <time_frame>12 months, and Last assessment which is either at Month 12 or at early discontinuation</time_frame>
        <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod</title>
            <description>fingolimod 0.5 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Disease Modifying Therapy</title>
            <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From in Brain Volume From Month 12 to Last Visit (Randomized)</title>
          <description>Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI</description>
          <population>Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
          <units>percent change in brain volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change at 12 months (n=323, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.396" spread="0.7825"/>
                    <measurement group_id="O2" value="-0.555" spread="0.7181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change at Last assessment (n=370, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.385" spread="0.7690"/>
                    <measurement group_id="O2" value="-0.420" spread="0.6423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score</title>
        <description>Summary statistics for Medication Satisfaction Questionnaire[Question: “Overall, how satisfied are you with your current medication?”] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT</description>
        <time_frame>Baseline, 1 month, 3 months, 6 months, 9 months, at 12 months &amp; Last assessment during randomized phase which is either at Month 12 or at early discontinuation</time_frame>
        <population>Full analysis set (FAS) includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod</title>
            <description>fingolimod 0.5 mg once a day</description>
          </group>
          <group group_id="O2">
            <title>Disease Modifying Therapy (DS-DMT)</title>
            <description>2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score</title>
          <description>Summary statistics for Medication Satisfaction Questionnaire[Question: “Overall, how satisfied are you with your current medication?”] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT</description>
          <population>Full analysis set (FAS) includes all the patients who received at least one dose of study medication and had information on the primary end point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="4.7"/>
                    <measurement group_id="O2" value="16" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="10.3"/>
                    <measurement group_id="O2" value="13" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="13.6"/>
                    <measurement group_id="O2" value="39" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" spread="29.0"/>
                    <measurement group_id="O2" value="61" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="16.4"/>
                    <measurement group_id="O2" value="46" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="19.6"/>
                    <measurement group_id="O2" value="31" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="6.5"/>
                    <measurement group_id="O2" value="17" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219" spread="0"/>
                    <measurement group_id="O2" value="205" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="1.9"/>
                    <measurement group_id="O2" value="29" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="3.3"/>
                    <measurement group_id="O2" value="37" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="1.9"/>
                    <measurement group_id="O2" value="52" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="7.5"/>
                    <measurement group_id="O2" value="74" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="12.1"/>
                    <measurement group_id="O2" value="89" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" spread="37.5"/>
                    <measurement group_id="O2" value="97" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" spread="35.9"/>
                    <measurement group_id="O2" value="40" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="0"/>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.2"/>
                    <measurement group_id="O2" value="19" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="2.7"/>
                    <measurement group_id="O2" value="38" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="2.7"/>
                    <measurement group_id="O2" value="42" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="11.1"/>
                    <measurement group_id="O2" value="53" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="10.4"/>
                    <measurement group_id="O2" value="73" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" spread="37.0"/>
                    <measurement group_id="O2" value="91" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="34.9"/>
                    <measurement group_id="O2" value="30" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="0"/>
                    <measurement group_id="O2" value="82" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="2.0"/>
                    <measurement group_id="O2" value="9" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="3.8"/>
                    <measurement group_id="O2" value="11" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="2.8"/>
                    <measurement group_id="O2" value="13" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="6.3"/>
                    <measurement group_id="O2" value="24" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="14.4"/>
                    <measurement group_id="O2" value="46" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="32.7"/>
                    <measurement group_id="O2" value="67" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" spread="38.0"/>
                    <measurement group_id="O2" value="26" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="0"/>
                    <measurement group_id="O2" value="232" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="1.9"/>
                    <measurement group_id="O2" value="4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="2.2"/>
                    <measurement group_id="O2" value="6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="3.2"/>
                    <measurement group_id="O2" value="12" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="5.7"/>
                    <measurement group_id="O2" value="15" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="11.4"/>
                    <measurement group_id="O2" value="29" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="36.5"/>
                    <measurement group_id="O2" value="58" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" spread="39.2"/>
                    <measurement group_id="O2" value="29" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" spread="0"/>
                    <measurement group_id="O2" value="275" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="2.0"/>
                    <measurement group_id="O2" value="3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="2.0"/>
                    <measurement group_id="O2" value="4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="3.1"/>
                    <measurement group_id="O2" value="4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="7.7"/>
                    <measurement group_id="O2" value="8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="9.7"/>
                    <measurement group_id="O2" value="22" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="32.8"/>
                    <measurement group_id="O2" value="60" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" spread="42.7"/>
                    <measurement group_id="O2" value="26" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="0"/>
                    <measurement group_id="O2" value="301" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment, Extremely dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="3.3"/>
                    <measurement group_id="O2" value="46" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment, Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="3.5"/>
                    <measurement group_id="O2" value="61" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment, Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="5.3"/>
                    <measurement group_id="O2" value="57" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment,Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="10.5"/>
                    <measurement group_id="O2" value="58" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment, Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="10.0"/>
                    <measurement group_id="O2" value="69" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment, Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="29.8"/>
                    <measurement group_id="O2" value="94" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment, Extremely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" spread="37.7"/>
                    <measurement group_id="O2" value="37" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last assessment, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0"/>
                    <measurement group_id="O2" value="6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fingolimod</title>
          <description>Fingolimod</description>
        </group>
        <group group_id="E2">
          <title>MS DMT</title>
          <description>MS DMT</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Jejunal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agoraphobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="282" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="291" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>(862) 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

